Barbara Zink - Basilea Pharmaceutica Insider

Basilea Pharmaceutica AG -- USA Stock  

USD 75.68  1.57  2.03%

Head - Corporate Development

We currently do not have informatin regarding Barbara Zink. This executive tanure with Basilea Pharmaceutica AG is not currenlty determined.
        
41 61 606 11 11  http://www.basilea.com

Management Efficiency

The company has return on total asset (ROA) of (7.18) % which means that it has lost $7.18 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (4.6) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 197.51 M in total debt. Basilea Pharmaceutica AG has Current Ratio of 2.92 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Entity Summary

Basilea Pharmaceutica Ltd., together with its subsidiaries, operates as an integrated biopharmaceutical company. Basilea Pharmaceutica AG (BPMUF) is traded on OTC Market in USA. It is located in Basel, and employs 250 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Basilea Pharmaceutica AG to your portfolio

Top Management

Basilea Pharmaceutica AG Leadership Team
Thomas Rinderknecht, Director, Ph.D
Daniel Lew, Director
Martin Nicklasson, Chairman, Ph.D
Domenico Scala, Director
David Veitch, Executive
Donato Spota, CFO
Guenter Ditzinger, CTO, Ph.D
Barbara Zink, Executive
Achim Kaufhold, Executive
Ronald Scott, CEO
Nicole Onetto, Director, Ph.D
Alf Nicklasson, Director, Ph.D
Heidi McDaid, Executive
Thomas Werner, Director
Ingrid HeinzeKrauss, CTO, Ph.D
Laurenz Kellenberger, Executive, Ph.D
Steven Skolsky, Director
HansBeat Guertler, Director
Peer Schroeder, Executive

Stock Performance

Basilea Pharmaceutica Performance Indicators